These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31512988)

  • 1. Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats.
    Burke NN; Li Y; Deaver DR; Finn DP; Roche M; Eyerman DJ; Sanchez C; Kelly JP
    J Psychopharmacol; 2019 Dec; 33(12):1620-1627. PubMed ID: 31512988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats.
    Burke NN; Ferdousi M; Deaver DR; Finn DP; Roche M; Kelly JP
    Neuropharmacology; 2019 Mar; 146():327-336. PubMed ID: 30553825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid system modulators buprenorphine and samidorphan alter behavior and extracellular neurotransmitter concentrations in the Wistar Kyoto rat.
    Smith KL; Cunningham JI; Eyerman DJ; Dean RL; Deaver DR; Sanchez C
    Neuropharmacology; 2019 Mar; 146():316-326. PubMed ID: 30448421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.
    Almatroudi A; Husbands SM; Bailey CP; Bailey SJ
    J Psychopharmacol; 2015 Jul; 29(7):812-21. PubMed ID: 26045511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
    Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
    Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant-like effects of buprenorphine in rats are strain dependent.
    Browne CA; van Nest DS; Lucki I
    Behav Brain Res; 2015 Feb; 278():385-92. PubMed ID: 25453747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
    Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.
    Falcon E; Maier K; Robinson SA; Hill-Smith TE; Lucki I
    Psychopharmacology (Berl); 2015 Mar; 232(5):907-15. PubMed ID: 25178815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.
    Callaghan CK; Rouine J; Dean RL; Knapp BI; Bidlack JM; Deaver DR; O'Mara SM
    Brain Behav Immun; 2018 Jan; 67():152-162. PubMed ID: 28844812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
    Ragguett RM; Rong C; Rosenblat JD; Ho RC; McIntyre RS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):475-482. PubMed ID: 29621905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats.
    Smith SL; Dean RL; Todtenkopf MS; Heal DJ
    J Psychopharmacol; 2019 Mar; 33(3):383-391. PubMed ID: 30676189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
    Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
    J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents.
    Rosenzweig-Lipson S; Sabb A; Stack G; Mitchell P; Lucki I; Malberg JE; Grauer S; Brennan J; Cryan JF; Sukoff Rizzo SJ; Dunlop J; Barrett JE; Marquis KL
    Psychopharmacology (Berl); 2007 Jun; 192(2):159-70. PubMed ID: 17297636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.
    Almatroudi A; Ostovar M; Bailey CP; Husbands SM; Bailey SJ
    Br J Pharmacol; 2018 Jul; 175(14):2869-2880. PubMed ID: 28967123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
    Robinson SA; Erickson RL; Browne CA; Lucki I
    Behav Brain Res; 2017 Feb; 319():96-103. PubMed ID: 27818236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of oral buprenorphine, oral naltrexone or morphine on the effects of laparotomy in the rat.
    Liles JH; Flecknell PA; Roughan J; Cruz-Madorran I
    Lab Anim; 1998 Apr; 32(2):149-61. PubMed ID: 9587897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.
    Carr GV; Bangasser DA; Bethea T; Young M; Valentino RJ; Lucki I
    Neuropsychopharmacology; 2010 Feb; 35(3):752-63. PubMed ID: 19924112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining pindolol and paroxetine in an animal model of chronic antidepressant action--can early onset of action be detected?
    Cryan JF; McGrath C; Leonard BE; Norman TR
    Eur J Pharmacol; 1998 Jul; 352(1):23-8. PubMed ID: 9718263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies.
    Zhang H; Shi YG; Woods JH; Watson SJ; Ko MC
    Eur J Pharmacol; 2007 Sep; 570(1-3):89-96. PubMed ID: 17601558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment of Major Depressive Disorder.
    Bidlack JM; Knapp BI; Deaver DR; Plotnikava M; Arnelle D; Wonsey AM; Fern Toh M; Pin SS; Namchuk MN
    J Pharmacol Exp Ther; 2018 Nov; 367(2):267-281. PubMed ID: 30108159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.